AG真人官方

Heidi L. Wagner, a director of Wave Life Sciences Ltd. (WVE), received equity awards on 08/11/2025 under the 2025 Non-Employee Director Compensation Policy. The filing shows a grant of 12,700 restricted share units (RSUs) that vest 100% on the earlier of the company鈥檚 2026 annual general meeting or August 11, 2026. Following the reported transactions, the reporting person beneficially owns 44,930 ordinary shares directly.

The filing also discloses a share option covering 76,200 ordinary shares with an exercise price of $8.105, shown as acquired on 08/11/2025 and expiring on 08/11/2030. That option vests 100% on the earlier of the 2026 annual general meeting or August 11, 2026, and is reported as 76,200 derivative securities beneficially owned following the transaction.

HENRY CHRISTIAN O, a director of Wave Life Sciences Ltd. (WVE), reported compensation and trading activity. The director was granted 12,700 restricted share units (RSUs) and 76,200 share options under the 2025 Non-Employee Director Compensation Policy, with both awards vesting 100% on the earlier of the companys 2026 annual general meeting or August 11, 2026. The reporting person also sold 9,670 ordinary shares pursuant to a Rule 10b5-1 trading plan adopted November 24, 2024, at a weighted-average price of $8.81 per share (sales ranged $8.45 to $9.03). Following these transactions the report lists 29,645 ordinary shares and 76,200 options beneficially owned, held directly.

Wave Life Sciences director Adrian Rawcliffe received equity awards on 08/11/2025 comprising both restricted share units and stock options. The filing shows a grant of 12,700 restricted share units (RSUs) and a grant of 76,200 options with an exercise price listed as $8.105. The RSUs and options vest as to 100% on the earlier of the company鈥檚 2026 annual general meeting or August 11, 2026, and the option listing shows an expiration date of 08/11/2030. The filing reports 28,815 ordinary shares beneficially owned by Rawcliffe following these awards. These items are recorded as director compensation under the company鈥檚 2025 Non-Employee Director Compensation Policy.

Gregory L. Verdine, a director of Wave Life Sciences Ltd. (WVE), received director compensation consisting of 12,700 restricted share units (RSUs) and a share option covering 76,200 ordinary shares with an exercise price of $8.105. Following the RSU grant, his reported direct beneficial ownership is 295,217 ordinary shares.

The RSUs vest 100% on the earlier of the company鈥檚 2026 annual general meeting or August 11, 2026. The option vests on the same schedule and has an expiration date of August 11, 2030. Both awards were granted under the 2025 Non-Employee Director Compensation Policy.

Wave Life Sciences (WVE) filed a Form 144 disclosing a proposed sale of 9,670 common shares to be executed through J.P. Morgan Securities on Nasdaq with an approximate sale date of 08/13/2025. The filing lists an aggregate market value of $74,459 and notes 159,140,460 shares outstanding, indicating the planned sale represents a very small fraction of the company鈥檚 shares. The securities were acquired as Restricted Stock Units from the issuer on 08/12/2025, with payment noted as cash on that date. The filer reports no securities sold in the prior three months and makes the standard representation about lacking undisclosed material adverse information.

Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of 15,016,500 ordinary shares of Wave Life Sciences, representing 9.65% of the class based on 155,562,665 ordinary shares outstanding as reported in the company's proxy. The filing is submitted on Schedule 13G (Amendment No. 4) and shows 0 sole voting or dispositive power and 15,016,500 shares of shared voting and dispositive power, held through Adage Capital Partners, L.P.

The filing includes a certification that the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer, indicating a stated passive investment intent.

Wave Life Sciences Ltd. shareholders at the Annual General Meeting on August 5, 2025 approved an amendment increasing the companys 2021 Equity Incentive Plan by 8,000,000 ordinary shares. A quorum of 145,170,578 of 159,227,061 eligible shares (91.17%) was present or represented by proxy. The equity plan amendment passed 105,936,049 for to 24,647,485 against.

Shareholders re-elected nine directors to serve until the 2026 meeting, re-appointed KPMG LLP as auditor with 144,541,282 votes in favor, approved non-employee director compensation and a general share allotment authorization, and supported annual advisory votes on executive compensation. Voting records show significant opposition on several proposals and nominees as reflected by multi-million vote totals against certain items.

What happened: Wave Life Sciences director Ken Takanashi sold 4,872 ordinary shares on August 5, 2025 to cover taxes from restricted share units that vested.

Why it matters: The sale was executed under a pre-established 10b5-1 trading plan, indicating it was planned in advance rather than a discretionary decision. After the transaction he still directly beneficially owns 5,716,303 shares, so this was a small, routine tax-withholding sale rather than a material exit.

What the filing shows: The Form 4 reports that Tan Aik Na, a director of Wave Life Sciences (WVE), sold 1,127 ordinary shares on August 5, 2025. The sale was made to cover taxes tied to the vesting of restricted share units and was executed pursuant to a 10b5-1 trading plan at a price of $8.75 per share. After the transaction the reporting person beneficially owned 14,988 shares.

Why the filing exists: This is a standard insider disclosure that records an insider sale made for tax withholding related to equity compensation and documents that the sale followed a prearranged plan.